GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended Blenrep ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...

The recommendation by the Committee for Medicinal Products for Human Use--also known as CHMP--follows the approval of Blenrep combinations by the U.K.'s Medicines and Healthcare products Regulatory ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma ...

(Alliance News) - GSK PLC on Friday said its drug Blenrep has received a "positive opinion" from the European Medicines Agency's Committee for Medicinal Products for Human Use.

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its ...

CHMP gives positive opinions for new drugs from GSK, Roche & SpringWorks, including GSK's Blenrep, Roche's Itovebi & ...

GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there, but was withdrawn from sale after it failed a ...